- , Jan. . . May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. . 02% rallied 1. . The company focuses on specific conditions such as lambert-eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), musk-myasthenia gravis. 66 short of its 52-week high ($22. . closed $10. . The stock's rise snapped a two-day losing streak. . See how Catalyst Pharmaceuticals compares to its main competitors: Merck has the most employees (74,000). If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. closed $9. . . The stock's rise snapped a two-day losing streak. . . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. 11), which the company achieved on January 13th. Market capitalization of Catalyst Pharmaceuticals (CPRX) Market cap: $1. . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. Catalyst Pharmaceuticals Inc. . CPRX inched 0. . . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. CPRX inched 0. Shares of Catalyst Pharmaceuticals Inc. . 3M. Catalyst Pharmaceuticals Competitors. Catalyst Pharmaceuticals top competitors are SMP Pharmacy Solutions, BRCR Global and Biotest Pharmaceuticals Corporation and they have annual revenue of $17. 30% advanced 2. 11), which the company achieved on January 13th. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . . Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA. . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. See insights on Catalyst Pharmaceuticals including office. The conference is set to sell-out again. . 11), which the company achieved on January 13th. 02% rallied 1. The stock's rise snapped a two-day losing streak. The stock's rise snapped a two-day losing streak. 09 below its 52-week high ($22. . . Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. . PFE, -0. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. 02% to $12. . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more.
- . Catalyst Pharmaceuticals Inc. 02% rallied 1. 02% to $12. Add company. 44% to $17. . 66 short of its 52-week high ($22. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. As of June 30, 2020, the last business day of the Registrant's most recently completed second quarter, the aggregate market value of all voting, and non-voting common equity held by non-affiliates was $444,887,344. CPRX, +1. is a commercial-stage biopharmaceutical company. 66 Thursday, on what proved to be an all-around grim trading session for the stock. 75-0. The stock demonstrated. 71%fell 0. . Catalyst Pharmaceuticals Inc. Add company. Securities and Exchange Commission ("SEC. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. 09 below its 52-week high ($22. , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. CPRX shed 1. Peers & Competitors.
- . . Follow $11. 36 below its 52-week high ($22. . . . . . A. Oct 10, 2022 · Catalyst Pharmaceuticals CPRX stock has skyrocketed 80. How Much Does Catalyst Pharmaceuticals Pay? There is a significant gap between what Catalyst Pharmaceuticals pays the bottom 10 percent of earners and the top 10 percent of earners. . 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. The conference is set to sell-out again. 02% rallied 1. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. . Study Catalyst Pharmaceuticals's history, mission, products/services, target market and competition. Founded in 1994 and developed around strong, innovative principles in the management of prescription drug programs, Catalyst Rx currently manages more than five million members located in the United States and Puerto Rico. How Much Does Catalyst Pharmaceuticals Pay? There is a significant gap between what Catalyst Pharmaceuticals pays the bottom 10 percent of earners and the top 10 percent of earners. . Despite its losses, the stock outperformed some of its competitors Wednesday. Catalyst Pharmaceuticals Inc. . . . Catalyst Pharmaceuticals Inc. 44% to $16. . 82, Pfizer Inc. 36% higher to $16. . , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. CORAL GABLES, Fla. As you might. . . . . The stock's rise snapped a two-day losing streak. (CPRX) is performing against its competitors. CPRX inched 0. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. . . . CPRX, +1. 11), which the company achieved on January 13th. 30% advanced 2. . . The stock underperformed when compared to some of its competitors. . 44% to $17. . . Catalyst Pharmaceuticals, Inc. . . As you might. . PFE, +0. . closed $6. . . . Competitor Summary. . . . CPRX, +1. 11), which the company achieved on January 13th. . The stock's rise snapped a two-day losing streak. 08, -2. 02% to $12. . .
- 92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . As you might. See how Catalyst Pharmaceuticals compares to its main competitors: Merck has the most employees (74,000). 02% to $12. 02% to $12. . . 75-0. Catalyst Pharmaceuticals Inc. . In some cases apparently high growth rates may be caused by data that weren't available in. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. With. . 79% fell 1. 3:. Future Competition: Catalyst Pharmaceuticals's Fastest Growing Competitors These companies are in the same general field as Catalyst Pharmaceuticals and are rapidly expanding. 0 / 100. public. CORAL GABLES, Fla. . The conference is set to sell-out again. . ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. Peers & Competitors. . 75-0. Expected to be Accretive in 2023. . . . . We have conducted a comparative analysis of the balance sheet and the income statement of Catalyst Pharmaceuticals, Inc. Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. . The stock outperformed some of its competitors Friday, as Johnson & Johnson JNJ, -0. Shares of Catalyst Pharmaceuticals Inc. . 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. . . 21 B According to Catalyst Pharmaceuticals's latest financial reports the company's current revenue (TTM) is $0. closed $9. 91% to $43. 33 (-2. 97% to $151. Founded in 1994 and developed around strong, innovative principles in the management of prescription drug programs, Catalyst Rx currently manages more than five million members located in the United States and Puerto Rico. . 30% to $12. . . . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. . The stock's rise snapped a two-day losing streak. 32% fell. . 30% advanced 2. . 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. Discover information and data insights on Catalyst Pharmaceuticals Inc key competitors and market peers. . ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. 33 (-2. As you might. . Shares of Catalyst Pharmaceuticals Inc. Shares of Catalyst Pharmaceuticals Inc. . 7 M: Pfizer Inc. Get an overview of Catalyst Pharmaceuticals's strategies within its core industry. . 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Market capitalization of Catalyst Pharmaceuticals (CPRX) Market cap: $1. 11), which the company achieved on January 13th. . . The award's lead sponsor is business leader Lorin Johnson; DLA Piper is co-sponsor. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. We have conducted a comparative analysis of the balance sheet and the income statement of Catalyst Pharmaceuticals, Inc. . . . See how Catalyst Pharmaceuticals compares to its main competitors: Merck has the most employees (74,000). Peers & Competitors. . . 32 Billion.
- Follow $11. . . CPRX shed 1. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Catalyst Pharmaceuticals Inc. . 30% advanced 2. closed $6. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . . 11), which the company achieved on January 13th. 30% to $12. . . . Discover information and data insights on Catalyst Pharmaceuticals Inc key competitors and market peers. 82, Pfizer Inc. . 03 short of its 52-week high ($22. . . . 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. Salaries vary by department as. 92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the. . Peers & Competitors. . Shares of Catalyst Pharmaceuticals Inc. 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. 32% fell. . , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. . Learn more about Catalyst Pharmaceuticals's competitors and. 73%) 4:00 PM 05/24/23. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . Shares of Catalyst Pharmaceuticals Inc. . (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. Compare financial ratios of 10,000 largest U. . Aug 9, 2022 · Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53. . Shares of Catalyst Pharmaceuticals Inc. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . . 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. CPRX, +2. Questcor would be one of the main competitors in this space, however, the price of Acthar gel is over $28,000 per vial. 11), which the company achieved on January 13th. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. Find contact information for Catalyst Pharmaceuticals. It delivers a detailed strategic analysis of the company's business, examining its performance in the market over a period of time. Aug 9, 2022 · Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53. The award's lead sponsor is business leader Lorin Johnson; DLA Piper is co-sponsor. . 21 hours ago · The competition will occur during Venture Atlanta, scheduled for September 27-28, 2023, in Atlanta at The Woodruff Arts Center and Atlanta Symphony Hall. Aug 9, 2022 · Achieved Record Q2 2022 FIRDAPSE® Net Product Revenues of $53. . 02% to $12. . 02% rallied 1. . 44% to $17. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. . Catalyst Pharmaceuticals’s Profile, Revenue and Employees. closed $10. The lawsuit is the latest chapter in a bizarre competition between Catalyst Pharmaceuticals and Jacobus Pharmaceutical, two small biotechs that both have FDA-approved drugs for a rare disease called Lambert-Eaton Myasthenic Syndrome, or LEMS. . 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. . Catalyst Pharmaceuticals Partners closed its last funding round on Nov 27, 2017 from a Post-IPO Equity round. The stock's rise snapped a two-day losing streak. A number of factors, including (i) the scope of protection from competition provided by the patent, and (ii) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019. . closed $9. 32 Billion. 02% rallied 1. . 11), which the company achieved on January 13th. . . . , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. closed $10. . CORAL GABLES, Fla. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA. Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops and commercializes prescription drugs targeting rare neurological and neuromuscular diseases. . Catalyst Pharmaceuticals Inc is a biopharmaceutical company. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. . 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. . Follow $11. The stock's rise snapped a two-day losing streak. . in January 2002 and has been its Chairman and President since July 2006 and also its Chief Executive Officer since January 2002. 30% to $12. Catalyst Pharmaceuticals Competitors. Compare financial ratios of 10,000 largest U. closed $10. . As you might. . 1st. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. 11), which the company reached on January 13th. 03 short of its 52-week high ($22. The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Catalyst Pharmaceuticals Inc. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. 91%fell 0. CPRX, +2. Compare financial ratios of 10,000 largest U. 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. Shares of Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals Inc's competitive profile, comparisons of quarterly results to its competitors, by sales, income, profitability, market share by products and services -. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. 66 short of its 52-week high ($22. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. Shares of Catalyst Pharmaceuticals Inc. . . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Catalyst Pharmaceuticals Inc. 11), which the company reached on January 13th. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Catalyst. PFE, +0. . .
Catalyst pharmaceuticals competitors
- 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. . closed $9. . As you might. . See how Catalyst Pharmaceuticals compares to its main competitors: Merck has the most employees (74,000). (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. . . . . McEnany, also known as Pat, Co-Founded Catalyst Pharmaceutical Partners Inc. . May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. . More on CPRX’s Competitors & Peers. , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . As you might. . . Revenue for Catalyst Pharmaceuticals (CPRX) Revenue in 2022 (TTM): $0. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. . 66 short of its 52-week high ($22. In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. 44% to $17. 92 Friday, on what proved to be an all-around favorable trading session for the stock market, with the. A. . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Shares of Catalyst Pharmaceuticals Inc. . PFE, +0. . . . 30% advanced 2. . . CPRX shed 1. . The stock demonstrated. . 73%) 4:00 PM 05/24/23. . CPRX shed 1. 27% fell 1. . Financials and Ratios. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. . . 1st. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, today announced that an article was recently. Dec 19, 2022 · Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. Catalyst Pharmaceuticals, Inc. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. CPRX, +1. . 91% to $43. 21 B. CPRX, +1.
- Manufacturing · United States · <25 Employees. . 21 hours ago · The competition will occur during Venture Atlanta, scheduled for September 27-28, 2023, in Atlanta at The Woodruff Arts Center and Atlanta Symphony Hall. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. 3rd. Founded in 1994 and developed around strong, innovative principles in the management of prescription drug programs, Catalyst Rx currently manages more than five million members located in the United States and Puerto Rico. 71%fell 0. . Catalyst Pharmaceuticals, Inc. . . is a commercial-stage biopharmaceutical company. As of May 2023 Catalyst Pharmaceuticals has a market cap of $1. CPRX advanced 1. . . May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Catalyst Pharmaceuticals. . Shares of Catalyst Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company. Catalyst Pharmaceuticals top competitors are SMP Pharmacy Solutions, BRCR Global and Biotest Pharmaceuticals Corporation and they have annual revenue of $17. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth.
- . . Shares of Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals Partners closed its last funding round on Nov 27, 2017 from a Post-IPO Equity round. 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. . . . . . ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. . Manufacturing · United States · <25 Employees. . Catalyst Pharmaceuticals’s Profile, Revenue and Employees. The stock demonstrated. . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. . . . . The main competitors of Catalyst Pharmaceuticals include Ligand Pharmaceuticals (LGND), Pliant Therapeutics (PLRX), Arcus Biosciences (RCUS),. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Learn more about Catalyst Pharmaceuticals's competitors and. Who are Catalyst Pharmaceuticals Partners 's competitors? Alternatives and possible competitors to Catalyst Pharmaceuticals Partners may include Alnylam Pharmaceuticals, Pliant Therapeutics, and Keros Therapeutics. Follow $11. Find contact information for Catalyst Pharmaceuticals. . . 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. . . . CPRX shed 1. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. . . Catalyst Pharmaceuticals, Inc. . Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. Catalyst Pharmaceuticals. . . The stock underperformed when compared to some of its competitors. . 44% to $17. . 66 short of its 52-week high ($22. . CPRX shed 1. 32 Billion. 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. 1st. The stock demonstrated. 73%) 4:00 PM 05/24/23. 39: $6. For the year, the company expects its two products to generate $375. 02% to $12. Shares of Catalyst Pharmaceuticals Inc. . , Jan. 02% to $12. . . Future Competition: Catalyst Pharmaceuticals's Fastest Growing Competitors These companies are in the same general field as Catalyst Pharmaceuticals and are rapidly expanding. The stock demonstrated. 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. 73%) 4:00 PM 05/24/23. 11), which the company achieved on January 13th. 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. Catalyst Pharmaceuticals Inc. . The stock demonstrated. If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. . The Company is focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. . .
- . . 71% to $163. . . . . . . Follow $11. . . Catalyst Pharmaceuticals. Despite its losses, the stock outperformed some of its competitors Wednesday, as Johnson & Johnson JNJ, +0. . . 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . . . is a commercial-stage biopharmaceutical company. . . 33 (-2. . . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. . 66 short of its 52-week high ($22. . . 66 short of its 52-week high ($22. Shares of Catalyst Pharmaceuticals Inc. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Shares of Catalyst Pharmaceuticals Inc. . The stock outperformed some of its competitors Friday, as Johnson & Johnson JNJ, -0. Shares of Catalyst Pharmaceuticals Inc. Shares of Catalyst Pharmaceuticals Inc. 75-0. . report ☒. 09 below its 52-week high ($22. . As you might. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. The stock demonstrated. . Catalyst Competitors. As you might. Catalyst Pharmaceuticals Inc. . . . 25% dropped 0. 97% lower. . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. Securities and Exchange Commission ("SEC. Shares of Catalyst Pharmaceuticals Inc. 11), which the company achieved on January 13th. 36% higher to $16. . Catalyst Pharmaceuticals Inc. . . 82, Pfizer Inc. . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . 11), which the company achieved on January 13th. Add company. 02% rallied 1. 3:. . A number of factors, including (i) the scope of protection from competition provided by the patent, and (ii) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019. 2nd. Add company. . . ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. . . 66 short of its 52-week high ($22. 66 short of its 52-week high ($22. . Catalyst Pharmaceuticals’s Profile, Revenue and Employees. 2nd. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. 30% advanced 2.
- is a commercial-stage biopharmaceutical company. . The lawsuit is the latest chapter in a bizarre competition between Catalyst Pharmaceuticals and Jacobus Pharmaceutical, two small biotechs that both have FDA-approved drugs for a rare disease called Lambert-Eaton Myasthenic Syndrome, or LEMS. May 23, 2023 · The main competitors of Catalyst Pharmaceuticals include Ligand Pharmaceuticals (LGND), Pliant Therapeutics (PLRX), Arcus Biosciences (RCUS), 89bio (ETNB), Keros Therapeutics (KROS), OPKO Health (OPK), Arvinas (ARVN), Agios Pharmaceuticals (AGIO), MoonLake Immunotherapeutics (MLTX), and Travere Therapeutics (TVTX). . . Catalyst Pharmaceuticals's competitors and similar companies include Omeros, Dermavant Sciences, Merus and ANI Pharmaceuticals. . . closed $6. CPRX, -0. Catalyst Pharmaceuticals Inc. 30% to $12. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. . . 08, -2. With the patient focus, the Company is engaged in developing a robust pipeline of cutting-edge, medicines for rare diseases. . 3 M: Alnylam Assist. PFE, +0. 36% higher to $16. Catalyst Pharmaceutical Partners (NASDAQ:NASDAQ:CPRX). closed $9. Follow $11. 66 short of its 52-week high ($22. . 44% to $16. Catalyst Pharmaceuticals Inc. This makes. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA. . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. closed $10. . . . . . closed $9. Catalyst Pharmaceuticals. May 23, 2023 · A team of two University of California, Davis, MBA students and a senior computer science major received the $20,000 first prize for the best innovation in the 23rd annual Big Bang! Business Competition on Tuesday (May 23). Find out how Catalyst Pharmaceuticals, Inc. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. The stock demonstrated. Find contact information for Catalyst Pharmaceuticals. CPRX, +2. Catalyst Pharmaceuticals, Inc. 36% higher to $16. . It delivers a detailed strategic analysis of the company's business, examining its performance in the market over a period of time. . Shares of Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. . . . Shares of Catalyst Pharmaceuticals Inc. . 75-0. The lowest-paid workers at Catalyst Pharmaceuticals make less than $36,000 a year, while the highest-paid workers earn over $83,000. . . . 62, Pfizer Inc. . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. . CPRX shed 1. 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. . Catalyst Pharmaceuticals Inc. . . . 44% to $16. 71% to $163. . . Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. . As of May 2023 Catalyst Pharmaceuticals has a market cap of $1. . If you are having trouble viewing this document, please contact Catalyst Pathways at 1-833-422-8259. 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. 75-0. Catalyst Pharmaceuticals Inc. . Mr. The award's lead sponsor is business leader Lorin Johnson; DLA Piper is co-sponsor. Follow $11. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Follow $11. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. The company focuses on specific conditions such as lambert-eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), musk-myasthenia gravis. For the Biotechnology subindustry, Catalyst Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below: * Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. 02% to $12. May 10, 2023 · CORAL GABLES, Fla. In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. 11), which the company achieved on January 13th. S. . . Catalyst Pharmaceuticals. Shares of Catalyst Pharmaceuticals Inc. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Catalyst Pharmaceuticals's competitors and similar companies include Omeros, Dermavant Sciences, Merus and ANI Pharmaceuticals. 80 / 100. 2nd. . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. Shares of Catalyst Pharmaceuticals Inc. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. 97% lower. . Catalyst Pharmaceuticals's main competitors include Omeros, Dermavant Sciences, Merus and ANI Pharmaceuticals. Business. 32 Billion. The company focuses on specific conditions such as lambert-eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), musk-myasthenia gravis. . Follow $11. . 02% rallied 1. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. The conference is set to sell-out again. . . Peers & Competitors. . 36% higher to $16. Compare Catalyst Pharmaceuticals to its top competitors. . CPRX inched 0. 36 below its 52-week high ($22. . 02% to $12. . . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. Catalyst Pharmaceuticals, Inc. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. Follow $11.
82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. Shares of Catalyst Pharmaceuticals Inc. . 55% to $162. . . 44% to $17. .
.
(CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth.
Catalyst Pharmaceuticals Inc.
.
.
09 below its 52-week high ($22.
. Now, Catalyst is suing the agency over last month’s approval of Jacobus’ drug. 11), which the company achieved on January 13th.
Shares of Catalyst Pharmaceuticals Inc.
.
11), which the company achieved on January 13th.
25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings.
. CPRX, +2.
staar score conversion chart
A number of factors, including (i) the scope of protection from competition provided by the patent, and (ii) those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2019.
36% higher to $16.
02% rallied 1.
36% higher to $16. . As you might. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.
Salaries vary by department as.
Catalyst Pharmaceuticals Inc. 55% to $162. Competitor Summary. 09 below its 52-week high ($22. . CPRX advanced 1. Oct 10, 2022 · Catalyst Pharmaceuticals CPRX stock has skyrocketed 80. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. 02% to $12. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Shares of Catalyst Pharmaceuticals Inc. .
30% to $12. . . .
.
.
.
.
.
. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. CPRX shed 1. For the Biotechnology subindustry, Catalyst Pharmaceuticals's WACC %, along with its competitors' market caps and WACC % data, can be viewed below: * Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA.
- . 11), which the company reached on January 13th. is a commercial-stage biopharmaceutical company. 30% to $12. Compare financial ratios of 10,000 largest U. . . . . The stock demonstrated. . Follow $11. 7 M: Pfizer Inc. public. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . The conference is set to sell-out again. . 30% to $12. Catalyst Pharmaceuticals Inc. Catalyst Competitors. . . . . With. . . Catalyst Pharmaceutical Partners (NASDAQ:NASDAQ:CPRX). . As you might. 71% to $163. . Shares of Catalyst Pharmaceuticals Inc. . Mr. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. The stock's rise snapped a two-day losing streak. . . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. closed $9. Despite its losses, the stock outperformed some of its competitors Wednesday. See insights on Catalyst Pharmaceuticals including office. . . . 44% to $17. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. . Leading biotech Catalyst Pharmaceuticals ( CPRX) beat Wall Street's 2023 guidance expectations, and CPRX stock jumped Thursday. As of June 30, 2020, the last business day of the Registrant's most recently completed second quarter, the aggregate market value of all voting, and non-voting common equity held by non-affiliates was $444,887,344. Follow $11. 3 M: Alnylam Assist. Catalyst Pharmaceuticals Inc. Discover information and data insights on Catalyst Pharmaceuticals Inc key competitors and market peers. . . . closed $6. . It focuses on developing and commercializing innovative therapies for people with rare,. In some cases apparently high growth rates may be caused by data that weren't available in. Catalyst Pharmaceuticals Inc is a biopharmaceutical company. Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. .
- . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. CORAL GABLES, Fla. 91%fell 0. 02% to $12. 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. . . . To report SUSPECTED ADVERSE REACTIONS, contact Catalyst Pharmaceuticals at 1-844-347-3277 (1844-FIRDAPSE) or FDA at 1-800-FDA-1088 or. 75-0. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. This makes. , March 08, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. . 44% to $16. . Catalyst Pharmaceuticals Partners closed its last funding round on Nov 27, 2017 from a Post-IPO Equity round. 36% higher to $16. . The stock demonstrated. . .
- . . Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. . . Dec 19, 2022 · Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. 36, Pfizer Inc. Peers & Competitors. . 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. . ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. 11), which the company achieved on January 13th. 36 below its 52-week high ($22. As you might. . . Alnylam Pharmaceuticals. 30% advanced 2. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. 02% to $12. May 23, 2023 · A team of two University of California, Davis, MBA students and a senior computer science major received the $20,000 first prize for the best innovation in the 23rd annual Big Bang! Business Competition on Tuesday (May 23). Catalyst Pharmaceuticals Inc. S. 30% advanced 2. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. May 23, 2023 · A team of two University of California, Davis, MBA students and a senior computer science major received the $20,000 first prize for the best innovation in the 23rd annual Big Bang! Business Competition on Tuesday (May 23). 30% advanced 2. . . This includes striving to. . . . . . PFE, +0. . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. 1st. . . 02% to $12. . . . 8 Million, with No Funded Debt Completed. 11), which the company achieved on January 13th. 44% to $17. . Shares of Catalyst Pharmaceuticals Inc. Market capitalization of Catalyst Pharmaceuticals (CPRX) Market cap: $1. Peers & Competitors. . Understand the market trends shaping the industry to gain a deep understanding of Catalyst Pharmaceuticals's strategic direction. 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. Follow $11. . Market capitalization of Catalyst Pharmaceuticals (CPRX) Market cap: $1. . . 2 days ago · In the last 30 days, shares of Catalyst Pharmaceuticals ( CPRX -0. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . Catalyst Pharmaceuticals Inc. The conference is set to sell-out again. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). . closed $9. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. CPRX shed 1. . 1 day ago · For Immediate ReleaseChicago, IL – May 24, 2023 – Today, Zacks Equity Research discusses Amphastar Pharmaceuticals AMPH, Dr. Shares of Catalyst Pharmaceuticals Inc. . . CPRX, +2. . Apr 10, 2023 · Catalyst Pharmaceuticals main competitors are WebMD, Merck, and Sanofi Genzyme. 02% to $12.
- . 21 B. 02% to $12. CPRX inched 0. CORAL GABLES, Fla. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. . . . . . , Jan. closed $9. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its. Catalyst Pharmaceuticals Partners closed its last funding round on Nov 27, 2017 from a Post-IPO Equity round. 25%) are down by 31%, with the stock crashing by 19% on May 10 when the company reported its first-quarter earnings. 5%. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company. (NASDAQ:CPRX) closed lower on Tuesday, May 23, closing at $12. Now, Catalyst is suing the agency over last month’s approval of Jacobus’ drug. The Enrollment Form may not load properly in all browsers. Learn about their Pharmaceuticals, Manufacturing market share, competitors, and Catalyst. Future Competition: Catalyst Pharmaceuticals's Fastest Growing Competitors These companies are in the same general field as Catalyst Pharmaceuticals and are rapidly expanding. PFE, -0. . . 78% to. . . . 44% to $17. with almost no competitors. . 11), which the company achieved on January 13th. (NASDAQ:CPRX) closed lower on Tuesday, May 23, closing at $12. . . 3rd. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA. 66 short of its 52-week high ($22. . . PFE, +0. Expected to be Accretive in 2023. . . . 7 M: Pfizer Inc. Peers & Competitors. . Jan 23, 2023 · Under the Federal Food, Drug, and Cosmetic Act, as amended by the Drug Price Competition and Patent Term Restoration Act of 1984, as amended, Catalyst has 45 days from receipt of the Notice Letter. (CPRX) is performing against its competitors. Catalyst Pharmaceuticals Inc. . . . Shares of Catalyst Pharmaceuticals Inc. . 76, and Abbott. Catalyst Pharmaceuticals Inc (Catalyst) is a biopharmaceutical company that develops and commercializes prescription drugs targeting rare neurological and neuromuscular diseases. Shares of Catalyst Pharmaceuticals Inc. CORAL GABLES, Fla. Catalyst Pharmaceuticals Inc. . . . 30% to $12. Catalyst Pharmaceuticals’s primary competitors include Acadia, Strongbridge Biopharma, Trusted Tablets and 19 more. 71% to $163. . Catalyst Pharmaceuticals Inc. . Shares of Catalyst Pharmaceuticals Inc. 14 B an increase over the years 2020 revenue that were of $0. The stock's rise snapped a two-day losing streak. S. 75-0. Catalyst Pharmaceutical Partners (NASDAQ:NASDAQ:CPRX). . . . . CPRX, -0. Catalyst Pharmaceuticals, Inc. 5%. . May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. Catalyst Pharmaceuticals, Inc. . The stock demonstrated. . 32 Billion.
- Shares of Catalyst Pharmaceuticals Inc. May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . Patrick J. 66 short of its 52-week high ($22. . More on CPRX’s Competitors & Peers. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Oct 10, 2022 · Catalyst Pharmaceuticals CPRX stock has skyrocketed 80. . . May 4, 2023 · Shares of Catalyst Pharmaceuticals Inc. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. . . ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. 3:. 11), which the company reached on January 13th. Learn about their Manufacturing, Pharmaceuticals market share, competitors, and Catalyst Pharmaceuticals's email format. 21 hours ago · The competition will occur during Venture Atlanta, scheduled for September 27-28, 2023, in Atlanta at The Woodruff Arts Center and Atlanta Symphony Hall. . The main competitors of Catalyst Pharmaceuticals include Ligand Pharmaceuticals (LGND), Pliant Therapeutics (PLRX), Arcus Biosciences (RCUS),. . 83 Friday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ. Catalyst Pharmaceuticals. Catalyst Pharmaceuticals Inc. . . Catalyst Pharmaceuticals’s Profile, Revenue and Employees. Reddy’s Laboratories RDY and Teva Pharmaceutical TEVA. . . 21 hours ago · The competition will occur during Venture Atlanta, scheduled for September 27-28, 2023, in Atlanta at The Woodruff Arts Center and Atlanta Symphony Hall. . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. CPRX, +2. ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. How Much Does Catalyst Pharmaceuticals Pay? There is a significant gap between what Catalyst Pharmaceuticals pays the bottom 10 percent of earners and the top 10 percent of earners. . . 45 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index. S. closed $9. . , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. 66 short of its 52-week high ($22. Follow $11. . . Catalyst Pharmaceuticals’s Profile, Revenue and Employees. . CORAL GABLES, Fla. CPRX shed 1. Catalyst Pharmaceuticals Inc. 30% advanced 2. 44% to $17. CORAL GABLES, Fla. . As of May 2023 Catalyst Pharmaceuticals has a market cap of $1. Despite its losses, the stock outperformed some of its competitors Wednesday. 25% dropped 0. Shares of Catalyst Pharmaceuticals Inc. . . Catalyst Pharmaceuticals Partners closed its last funding round on Nov 27, 2017 from a Post-IPO Equity round. . . . 02% to $12. Catalyst Pharmaceuticals Inc. CPRX shed 1. 11), which the company achieved on January 13th. 02% rallied 1. As you might. . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. . closed $9. . . 25% dropped 0. . Follow $11. . 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. 11), which the company achieved on January 13th. 08% fell 0. . 82 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. . . (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. 66 short of its 52-week high ($22. Peers & Competitors. Catalyst Pharmaceuticals competes with Agilent Technologies, AC Immune, Abeona Therapeutics, Acer Therapeutics, and Aurora Cannabis; as well as few. . . . . . Founded in 1994 and developed around strong, innovative principles in the management of prescription drug programs, Catalyst Rx currently manages more than five million members located in the United States and Puerto Rico. . Catalyst is a specialty pharmaceutical company focused on in-licensing and developing. Shares of Catalyst Pharmaceuticals Inc. report ☒. . Add company. . . . 02% to $12. CORAL GABLES, Fla. Catalyst Pharmaceuticals Inc. Peers & Competitors. 02 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ. 66 Thursday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index. Financials and Ratios. Get an overview of Catalyst Pharmaceuticals's strategies within its core industry. The trading price of Catalyst Pharmaceuticals Inc. . . . Future Competition: Catalyst Pharmaceuticals's Fastest Growing Competitors These companies are in the same general field as Catalyst Pharmaceuticals and are rapidly expanding. CPRX, +1. CPRX inched 0. . . , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. 44% to $17. Catalyst Pharmaceuticals Inc. , May 10, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals’s Profile, Revenue and Employees. (CPRX) key stats comparison: compare with other stocks by metrics: valuation, growth. 25, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. This includes striving to. . 03 short of its 52-week high ($22. . Catalyst Pharmaceuticals top competitors include: CareASSIST, Coherus COMPLETE, Recombinate, Interconnect What does Catalyst Pharmaceuticals do? The Enrollment Form may not load properly in all browsers. The stock demonstrated. Shares of Catalyst Pharmaceuticals Inc. ("Catalyst or the Company") (Nasdaq: CPRX) today reported financial results for the first quarter of 2023 and. The stock demonstrated. CPRX, +2. 55% to $162. Founded in 1994 and developed around strong, innovative principles in the management of prescription drug programs, Catalyst Rx currently manages more than five million members located in the United States and Puerto Rico.
. Catalyst Pharmaceuticals top competitors are SMP Pharmacy Solutions, BRCR Global and Biotest Pharmaceuticals Corporation and they have annual revenue of $17. May 23, 2023 · The main competitors of Catalyst Pharmaceuticals include Ligand Pharmaceuticals (LGND), Pliant Therapeutics (PLRX), Arcus Biosciences (RCUS), 89bio (ETNB), Keros Therapeutics (KROS), OPKO Health (OPK), Arvinas (ARVN), Agios Pharmaceuticals (AGIO), MoonLake Immunotherapeutics (MLTX), and Travere Therapeutics (TVTX).
anime trending instagram
- 82, Pfizer Inc. bawo ni meaning in english
- 7 M: Pfizer Inc. how to apply for emergency medicaid texas for child
- media article examplesCatalyst Pharmaceuticals Inc. victoria day fireworks toronto 2023